BOSTON, Oct. 29, 2012 (GLOBE NEWSWIRE) -- Sildenafil citrate (SC), a phosphodiesterase type 5 inhibitor, administered before, during and after radiation therapy improved overall sexual function of prostate cancer patients, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 54th Annual Meeting.
